The purpose of this study is to test a new educational video to help patients and doctors talk about CAR-T cell therapy, a treatment being used in cancer. \- Educational video tool for patients receiving CAR-T cell therapy.
This research study is a Feasibility Study, which is the first-time investigators are examining this educational video tool for patients receiving CAR-T cell therapy. The research study procedures include screening for eligibility, randomization and a series of questionnaires Participants will be randomized to one of 2 groups: * Group A: Educational video tool * Group B: Standard care Participants will be in the research study for a month after consent It is expected that about 80 participants will take part in this research study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
80
The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
Massachusetts General Hospital
Boston, Massachusetts, United States
Feasibility (enrollment and retention rates)
The primary endpoint is feasibility. The proposed video intervention will be deemed feasible if at least 60% of eligible patients are enrolled in the study.
Time frame: Up to 1 year
Knowledge about CAR-T cell therapy (CAR-T cell Knowledge Questionnaire)
To compare patient's knowledge about CAR-T cell therapy between groups as measured by the CAR-T cell therapy Knowledge Questionnaire (Score range 0-10). Higher scores indicating higher knowledge.
Time frame: up to 1 month
Psychological distress (Hospital Anxiety and Depression Scale (HADS)
To compare patient's psychological distress between groups as measured by the HADS. HADS Anxiety and Depression subscales range from 0-21, with higher scores indicating worse psychological distress.
Time frame: up to 1 month
Patient's self-efficacy (modified version of CASE-cancer)
To compare patient's self-efficacy between the groups as measured by a modified version of the Communication and Attitudinal Self-Efficacy Scale-Cancer (CASE-cancer) for patients receiving CAR-T cell therapy. The modified CASE ranges from 0-170 with higher scores indicating higher self-efficacy
Time frame: up to 1 month
Preferences for CAR T-cell therapy (single-item preference for CAR-T cell therapy)
To compare patient's preferences for CAR-T cell therapy between groups as measured by a single-item "Do you prefer to receive CAR-T cell therapy". We will compare proportion of patients stating "yes" to receiving CAR-T cell therapy between groups.
Time frame: up to 1 week
Decision Satisfaction around receipt of CAR-T cell therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
To compare patient's satisfaction around the decision to receive CAR-T cell therapy between groups as measured by a five-item Likert scale ranging from "Strongly Disagree" to "Strongly Agree" with statements about satisfaction regarding the decision to receive CAR-T cell therapy, with "Strongly Agree" indicating the highest decision satisfaction. We will compare the proportion of patients stating "Agree" or "Strongly Agree" to the six items between groups.
Time frame: up to 1 month
Acceptability of the video (intervention arm only)
To assess, in the intervention group only, patients' comfort with watching the video, whether they find the video helpful in their understanding of CAR T-cell therapy, and whether they would recommend it to others as measured by a 3-item survey. Each of the three items is a four-point Likert scale. Acceptability is defined as at least 80% of patients intervention reporting they felt "very comfortable" or "somewhat comfortable" on a four-point Likert scale when asked about their comfort watching the video.
Time frame: up to 1 month